Reaffirmed: GlaxoSmithKline (LON:GSK) Market Perform Rating Reiterated by equity analysts Bernstein; GBX 1399 Target in Place


GlaxoSmithKline (LON:GSK) Rating Reaffirmed

Recently, In analysts report revealed to investors on 10 December, GlaxoSmithKline (LON:GSK) shares have had their Market Perform Rating has reaffirmed by stock analysts at Bernstein, who currently has a GBX 1399 target on company. This target by Bernstein may imply the possibile upside of 6.03% from the last price.

From a total of 24 analysts covering GlaxoSmithKline PLC (LON:GSK) stock, 6 rate it a ”Buy”, 4 a “Sell”, and 20 a ”Hold”. This means that 20% of the ratings are positive. The highest target price is GBX 1800 while the lowest target price is GBX 1250. The mean of all analyst targets is GBX 1477.54 with a 11.73% above today’s (GBX 1318.65) stock price. GlaxoSmithKline PLC was the topic of 96 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. BNP Paribas maintained shares on December 9 with “Neutral” rating. Goldman Sachs maintained shares with “Buy” rating and GBX 1800 target share price in a report from a November 24. Liberum Capital maintained GSK stock in a recent report from December 3 with “Hold” rating. J.P. Morgan maintained the rating on November 20. J.P. Morgan has a “Neutral” rating and a GBX 1370 price target on shares. Finally, Bernstein maintained the stock with “Market Perform” rating in a report issued on a December 1.

Approximately 2.17M shares of stock traded hands. GlaxoSmithKline plc (LON:GSK) has declined 9.27% since May 13, 2015 and is downtrending. It has underperformed by 7.34% the S&P500.

Reaffirmed: GlaxoSmithKline (LON:GSK) Market Perform Rating Reiterated by equity analysts Bernstein; GBX 1399 Target in Place

GlaxoSmithKline plc. is a healthcare firm that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The company has a market cap of 63.85 billion GBP. The Firm operates in two divisions: Pharmaceuticals and Vaccines, and Consumer Healthcare. It has 6.48 P/E ratio. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.

According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.” Get a free copy of the Zacks research report on GlaxoSmithKline plc (GSK).